Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype
Standard
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype. / Poiré, Xavier; Labopin, Myriam; Polge, Emmanuelle; Ganser, Arnold; Socié, Gérard; Gedde-Dahl, Tobias; Forcade, Edouard; Finke, Jürgen; Chalandon, Yves; Bulabois, Claude-Eric; Yakoub-Agha, Ibrahim; Aljurf, Mahmoud; Kröger, Nicolaus; Blau, Igor Wolfgang; Nagler, Arnon; Esteve, Jordi; Mohty, Mohamad.
in: BONE MARROW TRANSPL, Jahrgang 59, Nr. 2, 02.2024, S. 264-269.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype
AU - Poiré, Xavier
AU - Labopin, Myriam
AU - Polge, Emmanuelle
AU - Ganser, Arnold
AU - Socié, Gérard
AU - Gedde-Dahl, Tobias
AU - Forcade, Edouard
AU - Finke, Jürgen
AU - Chalandon, Yves
AU - Bulabois, Claude-Eric
AU - Yakoub-Agha, Ibrahim
AU - Aljurf, Mahmoud
AU - Kröger, Nicolaus
AU - Blau, Igor Wolfgang
AU - Nagler, Arnon
AU - Esteve, Jordi
AU - Mohty, Mohamad
N1 - © 2023. The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2024/2
Y1 - 2024/2
N2 - Allogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML. A total of 236 patients were identified within the EBMT registry as having HDK comprising 95 pure (pHDK) and 141 with other cytogenetic abnormalities (HDK+). The 2-year probability of leukemia-free survival (LFS) was 50% for pHDK and 31% for HDK+ (p = 0.003). The 2-year probability of overall survival (OS) was 57% for pHDK and 36% for HDK+ (p = 0.007). The 2-year cumulative incidence of relapse (RI) was 22% for pHDK and 44% for HDK+ (p = 0.001). The 2-year probability of graft-versus-host disease (GvHD)-free and relapse-free survival (GRFS) was 36% for pHDK and 21% for HDK+ (p = 0.01). On multivariate analysis, pHDK remained associated with significantly better LFS, OS and GRFS and lower RI (all p-values <0.004). pHDK AML constitutes probably a distinct cytogenetic entity from HDK+ or other non-hyperdiploid CK AML with better outcomes after allo-HCT.
AB - Allogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML. A total of 236 patients were identified within the EBMT registry as having HDK comprising 95 pure (pHDK) and 141 with other cytogenetic abnormalities (HDK+). The 2-year probability of leukemia-free survival (LFS) was 50% for pHDK and 31% for HDK+ (p = 0.003). The 2-year probability of overall survival (OS) was 57% for pHDK and 36% for HDK+ (p = 0.007). The 2-year cumulative incidence of relapse (RI) was 22% for pHDK and 44% for HDK+ (p = 0.001). The 2-year probability of graft-versus-host disease (GvHD)-free and relapse-free survival (GRFS) was 36% for pHDK and 21% for HDK+ (p = 0.01). On multivariate analysis, pHDK remained associated with significantly better LFS, OS and GRFS and lower RI (all p-values <0.004). pHDK AML constitutes probably a distinct cytogenetic entity from HDK+ or other non-hyperdiploid CK AML with better outcomes after allo-HCT.
KW - Humans
KW - Retrospective Studies
KW - Hematopoietic Stem Cell Transplantation/adverse effects
KW - Leukemia, Myeloid, Acute/genetics
KW - Prognosis
KW - Karyotype
KW - Graft vs Host Disease/etiology
KW - Recurrence
KW - Transplantation Conditioning/adverse effects
U2 - 10.1038/s41409-023-02167-1
DO - 10.1038/s41409-023-02167-1
M3 - SCORING: Journal article
C2 - 38092959
VL - 59
SP - 264
EP - 269
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 2
ER -